A Randomized, Controlled Trial of Nasal Phenylephrine in Infants Hospitalized for Bronchiolitis

Shawn Ralston, Mahshid Roohi

Research output: Contribution to journalArticle

Abstract

Objective: To examine the hypothesis that pharmacologic treatment of nasal obstruction, specifically alpha-adrenergic nose drops, will decrease objective signs of respiratory distress in infants with bronchiolitis. Study design: Forty-one infants aged 3 weeks to 12 months hospitalized for viral bronchiolitis were enrolled in this double-blinded, placebo-controlled trial of topical 0.5% phenylephrine drops. The primary outcome measure was change in oxygen saturation. Secondary outcomes were changes in respiratory scores and vital signs. Results: There were no statistical differences in any of the outcome measures between groups. No adverse events were observed. Overall, participants showed an average 1.6 percentage point increase in their oxygen saturations (P = .002) and a 0.5-point improvement in respiratory score (P = .003) over the 30 minutes of the study. Conclusions: Topical nasal phenylephrine did not produce significant short-term improvements in clinical status in infants hospitalized for acute bronchiolitis.

Original languageEnglish (US)
JournalJournal of Pediatrics
Volume153
Issue number6
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Bronchiolitis
Phenylephrine
Nose
Randomized Controlled Trials
Viral Bronchiolitis
Outcome Assessment (Health Care)
Oxygen
Nasal Obstruction
Vital Signs
Adrenergic Agents
Placebos
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

A Randomized, Controlled Trial of Nasal Phenylephrine in Infants Hospitalized for Bronchiolitis. / Ralston, Shawn; Roohi, Mahshid.

In: Journal of Pediatrics, Vol. 153, No. 6, 01.01.2008.

Research output: Contribution to journalArticle

@article{e1ed9be840fd4256a835cde1005b2ad3,
title = "A Randomized, Controlled Trial of Nasal Phenylephrine in Infants Hospitalized for Bronchiolitis",
abstract = "Objective: To examine the hypothesis that pharmacologic treatment of nasal obstruction, specifically alpha-adrenergic nose drops, will decrease objective signs of respiratory distress in infants with bronchiolitis. Study design: Forty-one infants aged 3 weeks to 12 months hospitalized for viral bronchiolitis were enrolled in this double-blinded, placebo-controlled trial of topical 0.5{\%} phenylephrine drops. The primary outcome measure was change in oxygen saturation. Secondary outcomes were changes in respiratory scores and vital signs. Results: There were no statistical differences in any of the outcome measures between groups. No adverse events were observed. Overall, participants showed an average 1.6 percentage point increase in their oxygen saturations (P = .002) and a 0.5-point improvement in respiratory score (P = .003) over the 30 minutes of the study. Conclusions: Topical nasal phenylephrine did not produce significant short-term improvements in clinical status in infants hospitalized for acute bronchiolitis.",
author = "Shawn Ralston and Mahshid Roohi",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.jpeds.2008.06.003",
language = "English (US)",
volume = "153",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - A Randomized, Controlled Trial of Nasal Phenylephrine in Infants Hospitalized for Bronchiolitis

AU - Ralston, Shawn

AU - Roohi, Mahshid

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Objective: To examine the hypothesis that pharmacologic treatment of nasal obstruction, specifically alpha-adrenergic nose drops, will decrease objective signs of respiratory distress in infants with bronchiolitis. Study design: Forty-one infants aged 3 weeks to 12 months hospitalized for viral bronchiolitis were enrolled in this double-blinded, placebo-controlled trial of topical 0.5% phenylephrine drops. The primary outcome measure was change in oxygen saturation. Secondary outcomes were changes in respiratory scores and vital signs. Results: There were no statistical differences in any of the outcome measures between groups. No adverse events were observed. Overall, participants showed an average 1.6 percentage point increase in their oxygen saturations (P = .002) and a 0.5-point improvement in respiratory score (P = .003) over the 30 minutes of the study. Conclusions: Topical nasal phenylephrine did not produce significant short-term improvements in clinical status in infants hospitalized for acute bronchiolitis.

AB - Objective: To examine the hypothesis that pharmacologic treatment of nasal obstruction, specifically alpha-adrenergic nose drops, will decrease objective signs of respiratory distress in infants with bronchiolitis. Study design: Forty-one infants aged 3 weeks to 12 months hospitalized for viral bronchiolitis were enrolled in this double-blinded, placebo-controlled trial of topical 0.5% phenylephrine drops. The primary outcome measure was change in oxygen saturation. Secondary outcomes were changes in respiratory scores and vital signs. Results: There were no statistical differences in any of the outcome measures between groups. No adverse events were observed. Overall, participants showed an average 1.6 percentage point increase in their oxygen saturations (P = .002) and a 0.5-point improvement in respiratory score (P = .003) over the 30 minutes of the study. Conclusions: Topical nasal phenylephrine did not produce significant short-term improvements in clinical status in infants hospitalized for acute bronchiolitis.

UR - http://www.scopus.com/inward/record.url?scp=56049084435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049084435&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2008.06.003

DO - 10.1016/j.jpeds.2008.06.003

M3 - Article

C2 - 18657831

AN - SCOPUS:56049084435

VL - 153

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -